MoonLake Q1 cash $547.1M; positive FDA/EMA feedback for Phase 3 sonelokimab in HS

MoonLake Immunotherapeutics

Cash and equivalents $547.1M at March 31, 2024, expected to fund operations to end of 2026.
R&D expense $13.0M in Q1 (up from $8.1M prior Q) due to trial initiations; G&A $6.8M.
Positive FDA and EMA feedback for Phase 3 VELA program in HS; topline data expected mid-2025.
ARGO Phase 2 in PsA: up to 52% ACR50+PASI100 and 61% MDA at week 24, suggesting best-in-class profile.
Plans to initiate four additional trials in PPP, juvenile HS, seronegative spondyloarthritis in 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MoonLake Immunotherapeutics reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

MoonLake Immunotherapeutics filing history →

Source: SEC EDGAR

accession 0001821586-24-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.